Senores Pharma, a Gujarat-based pharmaceutical company, has seen massive interest from investors in its Initial Public Offering (IPO), which closed on December 24, 2024. The IPO, which opened on December 20, 2024, has been subscribed an incredible 93.41 times, indicating strong demand for its shares. Senores Pharma aims to raise a total of Rs 582 crore through the offering, having already secured Rs 260.6 crore from anchor investors.
Key IPO Details:
IPO Detail | Information |
---|---|
IPO Open Date | December 20, 2024 |
IPO Closing Date | December 24, 2024 |
Price Band | Rs 372 – Rs 391 per share |
Total Funds to be Raised | Rs 582 crore |
Retail Investment Minimum | Rs 14,858 (38 equity shares) |
Anchor Investor Commitment | Rs 260.6 crore |
Listing Date | December 30, 2024 |
Subscription Breakdown:
Senores Pharma’s IPO received an overwhelming subscription rate, with investors showing a strong interest in the offering. The IPO was subscribed a total of 93.41 times, demonstrating investor confidence in the company’s growth prospects. This is a promising sign for both retail and institutional investors.
- Retail Investors: The retail segment had to make a minimum investment of Rs 14,858, which corresponds to 38 equity shares. The retail portion was heavily oversubscribed, reflecting strong demand from individual investors.
- Grey Market Premium (GMP): As of December 25, 2024, the shares of Senores Pharma are trading in the grey market at a premium of Rs 230. This translates to a 58.8% premium over the IPO price, which suggests that the stock could list at around Rs 621 on December 30, 2024. While the grey market provides a sense of early investor sentiment, market experts caution against making investment decisions solely based on the grey market trends.
Senores Pharma’s Business and Market Presence
Senores Pharma primarily focuses on the regulated markets of the United States, Canada, and the United Kingdom while also maintaining a strong presence in 43 emerging markets across the globe. This broad geographical reach places Senores Pharma in a strong position to capture growth in both developed and emerging markets. The company’s business model is well-diversified, which is attractive to investors looking for a stable long-term investment.
Senores Pharma IPO Listing Date: What to Expect
Senores Pharma’s shares are scheduled to list on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE) on December 30, 2024. Investors who received allotments can expect to see their shares start trading on the exchanges at that time.
Upcoming Listing on BSE and NSE
Senores Pharma’s shares are set to list on the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) on December 30, 2024. Investors who have successfully received allotments can look forward to seeing the company’s stock traded publicly for the first time.
How to Check Allotment Status:
Investors who applied for the IPO can check their allotment status online through the BSE website or the registrar Link Intime India Pvt Ltd. The allotment process is expected to be completed soon, and investors can begin trading their shares once they are listed on the stock exchanges.
Conclusion:
Senores Pharma’s IPO has received overwhelming demand, with a 93x subscription and a GMP of Rs 230, indicating that the stock could make a strong debut on the BSE and NSE on December 30, 2024. The company’s global reach and focus on regulated markets make it an attractive investment option for those seeking growth in the pharmaceutical sector.
With strong backing from anchor investors and a solid business model, Senores Pharma is poised for a successful public listing. Investors who are fortunate enough to receive an allotment can expect the stock to experience significant gains, especially with the high premium reflected in the grey market. However, as always, investors should consider the company’s fundamentals and long-term prospects when making their investment decisions.
read more about IPO Updates on niftynews